Real-world data on efficacy of abatacept vs TNFi in ACPA-positive RA

Key clinical point: Abatacept significantly improved disease activity compared with tumor necrosis factor inhibitors (TNFi) in a real-world population of patients with established anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA).

Major finding: At 1-year, the mean change in clinical disease activity index (CDAI) score was significantly higher with abatacept vs TNFi (−16.78 vs −13.61; P  =  .020), with a higher proportion of patients receiving abatacept vs TNFi achieving CDAI remission or low disease activity (68% vs 52.6%; P  =  .013).

Study details: The data come from an observational cohort study that propensity-score matched 291 patients with ACPA-positive RA who initiated abatacept (n = 97) or TNFi (n = 194).

,

Disclosures: This study was sponsored by Bristol-Myers Squibb. The authors declared no conflicts of interest.

Source: Kim MJ, Lee S-K, et al. Efficacy of abatacept versus tumor necrosis factor inhibitors in anti-citrullinated protein antibody-positive patients with rheumatoid arthritis: Results from a Korean nationwide biologics registry. Rheumatol Ther. 2022 (Jun 18). Doi: 10.1007/s40744-022-00467-4